Get It Today...The RNAi Therapeutics Investment Guide for 2013

What is driving the RNAi Therapeutics market, where are the pockets of value creation, and where are the risks?

The 'RNAi Therapeutics Investment Guide 2013' will answer these questions and more.  The Guide should be particularly useful for the following audiences:

1) Drug developers which consider investing in RNAi Therapeutics drug development;

2) Drug developers already engaged in RNAi Therapeutics development to help position themselves in the competitive market place;

3) RNAi Therapeutics investors, especially those in the public markets to understand the market place dynamics and to help identify investment opportunities.

42 pages.

Table of Contents                                                        

                                                                               

Abstract                                                                                 

Table of Contents                                                                   

1. The RNAi Therapeutics Opportunity                                 

2. RNAi Therapeutics History                                               

            A. The Geek Phase (2002-5)                                    

            B. Irrational Exuberance (2005-8)                             

            C. Doubts and Despair (2008-11)                              

            D. Revival (2011-present)                                        

3. RNAi Therapeutics in 2013                                                

A.    State of the (RNAi Delivery) Art                                     

                        i. SNALP                                                        

   ii. Dynamic PolyConjugates                           

                        iii. GalNAc-siRNA Conjugates                      

                        iv. Self-delivering RNAi Triggers                   

                        v. Viral Delivery                                             

B. The RNAi Trigger IP Landscape in 2013             

C. Sector Tailwinds                                                    

  i. RNAi Therapeutics Hits Sweet Spot of Secular Drug Development Trend                                                                      

            ii. RNAi Therapeutics as Part of Oligonucleotide Therapeutics Resurgence

                                                                                    

D. RNAi Therapeutics Deal Dynamics in 2013          

E. Clinical Trial Catalysts in 2013                              

            i. TKM-PLK1                                                 

            ii. ALN-TTR02                                               

            iii. ALN-TTRsc                                               

            iv. RXI-109                                                     

            v. ARC520                                                      

            vi. Cal-1                                                          

4. Potential Pitfalls                                                                  

5. Outlook Beyond 2013                                                        

6. Company Profiles                                                               

A.    Publicly Traded Pure Plays                                   

                        i. Alnylam                                                       

                        ii. Arrowhead Research                                  

                        iii. Benitec                                                       

                        iv. Bioneer                                                       

                        v. ISIS Pharmaceuticals                                  

                        vi. Marina Biotech                                          

                        vii. RXi Pharmaceuticals                                 

                        ix. Silence Therapeutics                                  

                        x. Tekmira Pharmaceuticals                            

B.     Big Pharma Players                                               

                        i. Merck                                                           

                        ii. Novartis                                                      

                        iii. Takeda                                                       

                        iv. Other Big Pharmas, Including AstraZeneca          

C.     Privately Owned Pure Plays                                             

           D. Other RNA Therapeutics Companies and Technologies   

Extra: The Business of RNAi Therapeutics 2013 (slide presentation).

Extra: Presentation slides.

Keywords: Alnylam, Arrowhead Research, Benitec, Marina Biotech, RXi Pharmaceuticals, Silence Therapeutics, Tekmira, Merck, Novartis, Big Pharma, SNALP, DPC, GalNAc, conjugates, self-delivering RNAi triggers, Dicer-substrates, nucleic acid modifications, TTR amyloidosis/ALN-TTR, HBV/ARC520, PCSK9/hypercholesterolemia, PLK1/cancer, RNA Therapeutics, antisense-mediated gene knockdown, intellectual property, orphan diseases, liver, safety.

Pricing

Drug development companies up to 10 employees: 250 Euros/300 US dollars

Drug development companies over 10 employees: 500 Euros/600 US dollars

Other companies (e.g. financial institutions and investment funds): 400 Euros/500 US dollars

University libraries: 95 Euros/120 dollars

Individuals (private use only): 95 Euros/120 US dollars

Prices exclude 19% VAT for German customers (corporate and non-corporate) and non-corporate customers in the European Union.

Payments either by bank transfer or paypal.

When ordering, the following information is required:

Full name and address

Use (corporate, individual etc)

Billing name and address if different

Order by contacting me at myfirstname.mylastnameATgmail.com
My first name: dirk; my last name: haussecker